NCT05360927View on ClinicalTrials.gov

Safety and Tolerability of BDB-001 Injection in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 25, 2019

Primary Completion Date

December 25, 2020

Study Completion Date

December 25, 2020

Conditions
Healthy
Interventions
DRUG

BDB-001 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

Trial Locations (1)

100032

Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Beijing Defengrei Biotechnology Co.,Ltd

UNKNOWN

lead

Staidson (Beijing) Biopharmaceuticals Co., Ltd

INDUSTRY

NCT05360927 - Safety and Tolerability of BDB-001 Injection in Healthy Subjects | Biotech Hunter | Biotech Hunter